Pharnext announces the completion of the consolidation of its shares at the rate of 1 new share against 5,000 old, the start of trading of the shares resulting from the consolidation from Wednesday November 23, 2022, as well as a capital reduction – 22/11/2022 at 6:00 p.m.

PARIS, France, November 22, 2022 at 6:00 p.m. (CET) – Pharnext SA (FR001400BV89 – ALPHA) (the “Company”), an advanced clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases with no satisfactory therapeutic solution, announces today today the consolidation of its shares, as decided by its Board of Directors on September 26, 2022, at the rate of 1 new share with a nominal value of 1 euro against 5,000 old shares with a nominal value of 0 .0002 euro, as authorized by the General Meeting of June 17, 2022 under the terms of its eighth resolution.